Live feed
Filing
SCHEDULE 13D
SCHEDULE 13D0001193125-26-432028·CITY THERAPEUTICS, INC.
Schedule 13D ownership disclosure
CITY THERAPEUTICS, INC.
Common Stock, $0.0001 par value · CUSIP: 178782108
Event date: 2026-10-19
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- ARCH Venture Fund XII, L.P.Reported CIK 0001906837
Shares: 13,692,507 · Class: 25.6%
- ARCH Venture Partners XII, L.P.Reported CIK 0001979765
Shares: 13,692,507 · Class: 25.6%
- ARCH Venture Partners XII, LLCReported CIK 0001979548
Shares: 13,692,507 · Class: 25.6%
- Robert NelsenReported CIK 0001219042
Shares: 13,692,507 · Class: 25.6%
- Keith CrandellReported CIK 0001219039
Shares: 13,692,507 · Class: 25.6%
- Kristina BurowReported CIK 0001569248
Shares: 13,692,507 · Class: 25.6%
- Steven GillisReported CIK 0001229592
Shares: 13,692,507 · Class: 25.6%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001193125-26-432028
- Form type
- SCHEDULE 13D
- Filer
- CITY THERAPEUTICS, INC.
- CIK
- CIK 2143850
- Filed
- Oct 26, 2026
- Reporting period
- Oct 19, 2026
- Description
- Schedule 13D beneficial ownership